Posted on Nov 20, 2020
The EU could pay some €8.5 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in the talks has reportedly told Reuters.
The bloc has agreed to pay €15.5 per dose for the COVID-19 vaccine candidate being developed by Pfizer and BioNTech, according to Reuters source.
That would mean an overall price of up to €3.1 billion for 200 million doses, rising to €4.65 billion euros if another optional 100 million doses are purchased under the deal, the source said.
The pricing information, previously undisclosed, confirms the EU is paying less per dose than the United States for an initial supply of that vaccine, as reported by Reuters last week.
The deal includes an insurance for EU countries to get compensation if the companies divert doses to the United States, according to the source, who requested anonymity.
The EU has separately agreed to pay €10 per dose for an initial supply of 225 million doses of the vaccine candidate from CureVac, a discount from the €12 euros the company originally set as the price.
Follow EU Today on Social media: